RxDoctor Payments Data

Aidenojie Ihenyen, MD

Hospitalist · Hiram, GANPI 1073873113

Payments from drug & device makers

$519in general payments, 2019–2025

Across 20 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$104
  • Johnson & Johnson$89
  • AstraZeneca$57
  • Novartis$52
  • Galt Pharmaceuticals, LLC$44
  • Boston Scientific$33
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead1$104
Johnson & Johnson5$89
AstraZeneca3$57
Novartis2$52
Galt Pharmaceuticals, LLC1$44
Boston Scientific1$33
Nalu Medical, Inc.1$32
Relievant Medsystems, Inc.1$24
Pfizer1$21
Novo Nordisk1$20
Fisher Scientific Company L.L.C.1$16
E.r. Squibb & Sons, L.L.C.1$15
Boehringer Ingelheim1$13

How this compares

$519 in reported general payments places this provider in the 75th percentile of 812 hospitalist providers in Georgia.

See all hospitalist providers in Georgia

Medicare billing

Part B allowed, 2024
$102,866
Medicare patients
448
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$70,941
IngrezzaValbenazine Tosylate17$66,589
JardianceEmpagliflozin68$30,296
XifaxanRifaximin22$14,835
FarxigaDapagliflozin Propanediol28$10,149
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,779
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$6,644
Sevelamer Hcl14$6,112
TrulicityDulaglutide11$5,330
Pantoprazole Sodium160$4,965
Midodrine Hcl23$4,258
MyrbetriqMirabegron19$4,200
Advair HfaFluticasone Propion/Salmeterol12$3,828
Atorvastatin Calcium223$3,820
LantusInsulin Glargine,hum.Rec.Anlog49$3,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$70,941213 claims
Boehringer IngelheimJardiance$13$30,29668 claims
AstraZenecaFarxiga$57$10,14928 claims
Novo NordiskNovolog, Levemir$20$3,21734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 812 hospitalist providers in Georgia.

Other hospitalist in Hiram

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →